Antiviral agents articles from across Nature Portfolio

Antiviral agents are drugs that inhibit the spread of virus, for example by preventing replication of the genome, blocking entry to host cells, or inhibiting viral protein synthesis or viral assembly.

Latest Research and Reviews

Research
25 February 2023 | Open Access

Identification of SARS-CoV-2 M^pro inhibitors containing P1’ 4-fluorobenzothiazole moiety highly active against SARS-CoV-2

Effective antivirals are critical for combatting SARS-CoV-2 infections. Here, the authors develop two orally available small molecules, which specifically inhibit the activity of the SARS-CoV-2 main protease and potently block the infectivity and replication of various SARS-CoV-2 strains in cells and mice.
- Nobuyo Higashi-Kuwata
- , Kohei Tsuji
- & Hiroaki Mitsuya
Nature Communications 14, 1076
Research
09 February 2023 | Open Access

Ultra-long-acting in-situ forming implants with cabotegravir protect female macaques against rectal SHIV infection

In this study, the authors developed an ultra-long-acting injectable, biodegradable, and removable in-situ forming implant delivering cabotegravir (CAB ISFI). CAB ISFI was well tolerated and protected against multiple rectal SHIV challenges in female macaques.
- Isabella C. Young
- , Ivana Massud
- & S. Rahima Benhabbour
Nature Communications 14, 708
Research
23 January 2023 | Open Access

Botanical inhibitors of SARS-CoV-2 viral entry: a phylogenetic perspective
- Caitlin J. Risener
- , Sunmin Woo
- & Cassandra L. Quave
Scientific Reports 13, 1244
Research
15 December 2022 | Open Access

A proof-of-concept study on the genomic evolution of Sars-Cov-2 in molnupiravir-treated, paxlovid-treated and drug-naïve patients

A proof-of-concept study on the genomic evolution of SARS-CoV-2 during antiviral treatment reveals that Molnupiravir induces a higher in vivo intra-host variability compared to Paxlovid and drug-naive.
- Claudia Alteri
- , Valeria Fox
- & Carlo Federico Perno
Communications Biology 5, 1376
Research
26 November 2022 | Open Access

Intratracheal trimerized nanobody cocktail administration suppresses weight loss and prolongs survival of SARS-CoV-2 infected mice

Nagata, Utsumi, Asaka, Maeda et al. describe a nanobody, TP86, that potently neutralizes both BA.1 and BA.2 Omicron SARS-CoV-2 variants, and, when combined with the TP17 nanobody, broadly neutralizes all SARS-CoV-2 variants. This nanobody cocktail also suppresses weight loss and prolongs survival of SARS-CoV-2 infected human ACE2 transgenic mice.
- Kayoko Nagata
- , Daichi Utsumi
- & Akifumi Takaori-Kondo
Communications Medicine 2, 152
Research | 07 November 2022

Tecovirimat is effective against human monkeypox virus in vitro at nanomolar concentrations

Tecovirimat blocks replication of 2022 monkeypox virus isolate in vitro, supporting its use in ongoing human clinical trials.
- Gaëlle Frenois-Veyrat
- , Franck Gallardo
- & Jean-Nicolas Tournier
Nature Microbiology 7, 1951-1955

All Research & Reviews

News and Comment

Research Highlights | 21 February 2023

Early treatment for COVID-19

This study evaluates the efficacy of exogenous pegylated IFNλ in the treatment of patients with COVID-19.
- Andrea Du Toit
Nature Reviews Microbiology 21, 219
Research Highlights | 01 March 2022

Evaluating an RSV inhibitor

This study presents the results of a respiratory syncytial virus (RSV) challenge trial with EDP-938, a nonfusion replication inhibitor of RSV, showing effective lowering of viral load and symptoms, without apparent safety concerns.
- Andrea Du Toit
Nature Reviews Microbiology 20, 254
Research Highlights | 14 July 2021

Targeting viruses in their phase

The pathogenicity of SARS-CoV-2 and respiratory syncytial virus (RSV) involves mechanisms of liquid–liquid phase separation, which can be explored as targets for new antiviral therapeutics.
- Paulina Strzyz
Nature Reviews Molecular Cell Biology 22, 585
Research Highlights | 01 March 2021

Pan-serotype antiviral for dengue infection

This study identifies a promising preclinical candidate for the treatment of Dengue virus infection.
- Katie Kingwell
Nature Reviews Microbiology 19, 221
Editorial | 23 July 2020

COVID-19 therapies and vaccine landscape

Within a few weeks of the novel coronavirus genome sequence being published, numerous therapies and vaccines have entered clinical trials with a few showing great promise in alleviating symptoms and accelerating recovery.

Nature Materials 19, 809
News & Views | 23 October 2018

Targeting vesicle size

An amphipathic peptide has been engineered and is capable of penetrating the blood–brain barrier as well as possessing a potent antiviral activity against Zika and other mosquito-borne viruses.
- Jing Zou
- & Pei-Yong Shi
Nature Materials 17, 955-956

All News & Comment

Antiviral agents articles from across Nature Portfolio

Latest Research and Reviews

Identification of SARS-CoV-2 M^pro inhibitors containing P1’ 4-fluorobenzothiazole moiety highly active against SARS-CoV-2

Ultra-long-acting in-situ forming implants with cabotegravir protect female macaques against rectal SHIV infection

Botanical inhibitors of SARS-CoV-2 viral entry: a phylogenetic perspective

A proof-of-concept study on the genomic evolution of Sars-Cov-2 in molnupiravir-treated, paxlovid-treated and drug-naïve patients

Intratracheal trimerized nanobody cocktail administration suppresses weight loss and prolongs survival of SARS-CoV-2 infected mice

Tecovirimat is effective against human monkeypox virus in vitro at nanomolar concentrations

News and Comment

Early treatment for COVID-19

Evaluating an RSV inhibitor

Targeting viruses in their phase

Pan-serotype antiviral for dengue infection

COVID-19 therapies and vaccine landscape

Targeting vesicle size

Search

Quick links